Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ:ACRV)

1.990 -0.040 (-1.97%)
Streaming Delayed Price Updated: 11:15 AM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acrivon Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing,... 
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Announces $130 Million Private Placement Financing
From Acrivon Therapeutics, Inc
Via GlobeNewswire
News headline image
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.